Recent

% | $
Quotes you view appear here for quick access.

Carrizo Oil & Gas Inc. Message Board

theguywho2 9 posts  |  Last Activity: Jul 14, 2016 1:16 PM Member since: Mar 23, 2005
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Todays Press Release

    by theguywho2 Jul 14, 2016 11:30 AM
    theguywho2 theguywho2 Jul 14, 2016 1:16 PM Flag

    "While results from this current analysis are immature, a near doubling of
    response rates with aldoxorubicin suggests a highly active therapy which may benefit
    certain patients with soft tissue sarcoma," said Sant Chawla, M.D., F.R.A.C.P.,
    Principal Investigator and the Director of the Sarcoma Oncology Center in Santa
    Monica, California. "Because enrollment was interrupted by a clinical hold, both
    PFS and response data need to be analyzed at a future date to account for patients
    enrolled later in the trial. I look forward to this subsequent analysis providing
    a more complete understanding of aldoxorubicin's potential in this very challenging
    disease."
    Treatment-related adverse events for aldoxorubicin were consistent with those
    observed in prior studies. Aldoxorubicin was not associated with clinically significant
    cardiac, kidney or liver toxicities. The Company plans to present updated results
    of the study at an upcoming medical meeting.
    "The complexity, in terms of tumor diversity and primary location, makes
    soft tissue sarcoma extremely difficult to treat, especially in the relapsed and
    refractory setting, resulting in few treatment advances over the last four decades,"
    said Daniel Levitt, M.D., Ph.D., Executive vice president and Chief Medical Officer
    of CytRx. "This first-of-its-kind study in STS included a comparator arm with multiple
    regimens, allowing for treatments to be matched to specific sarcoma subtypes. Despite
    a requirement for this challenging study design, aldoxorubicin demonstrated markedly
    greater activity over investigator's choice therapy. That said, the unforeseen clinical
    hold that interrupted this study impacted the outcome of the current evaluation,
    underscoring a need for a subsequent analysis."
    "In over 550 patients treated to date, aldoxorubicin has demonstrated anti-tumor
    activity in multiple tumor types and has shown a manageable safety profile," said
    Steven A. Kriegsman, CytRx's Chairman and CEO. "With approximately $68.2 million
    in cash and equivalents as of our last 10-Q filing, CytRx is funded through the
    next Phase III STS trial analysis and through a readout of our global Phase IIb
    trial of aldoxorubicin in small cell lung cancer.

  • Reply to

    Todays Press Release

    by theguywho2 Jul 14, 2016 11:30 AM
    theguywho2 theguywho2 Jul 14, 2016 1:00 PM Flag

    No, it was released by Datamonitor (Comtex News) and contains additional quotes from Dr.Chawla, Dr. Levitt, and Kriegman.

  • theguywho2 by theguywho2 Jul 14, 2016 11:30 AM Flag

    Read todays press release about the recent phase 3 trials. There were definite improvements in many patients, interruption hurt. Not .aldoxorubicin failure.
    CytRx Corporation, a biopharmaceutical company, has announced the results of
    an analysis of its global, randomized, Phase III clinical trial of aldoxorubicin
    compared to investigator's choice therapy in patients with relapsed or refractory
    soft tissue sarcomas, or STS.
    In accordance with the FDA-granted special protocol assessment, the current
    analysis occurred following 191 progression events. Because enrollment was interrupted
    by a partial clinical hold in November 2014, this analysis did not provide for sufficient
    follow-up for the nearly two-thirds of patients who entered the Phase III study
    after the hold was resolved and enrollment resumed. This resulted in nearly half
    of all patients being censored (excluded) from the current progression free survival
    (PFS) evaluation. CytRx expects to conduct a second analysis, which will include
    longer patient follow-up and allow for greater maturation of all endpoints. The
    Company expects to announce the results of this evaluation and hold an end-of-Phase
    III meeting with the Food and Drug Administration (FDA) in the fourth quarter of
    2016. The partial clinical hold was related to a single patient enrolled in a compassionate
    use study, which was subsequently resolved successfully.
    For the current evaluation, the study did not show a significant difference
    between aldoxorubicin and investigator's choice therapy for PFS, with a median of
    4.17 months and 4.04 months, respectively, for the study's primary endpoint (hazard
    ratio: 0.91). However, the most immediate indications of therapeutic activity, objective
    response rate (ORR) and disease control rate (ORR + stable disease greater than
    or equal to 4 months), showed a near doubling in the aldoxorubicin arm compared
    to investigator's choice, including in patients who previously received treatment
    with doxorubicin. Disease

  • theguywho2 by theguywho2 Jul 12, 2016 11:31 AM Flag

    The company is also developing; in Phase IIb clinical trial in small cell lung cancer; in Phase II clinical trial in HIV-related Kaposi's sarcoma; in Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); in Phase Ib trial in combination with ifosfamide in patients with STS; and in Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. Also a Phase Ib pharmacokinetics clinical trial in patients with metastatic solid tumors. The company is also developing DK049 that is in pre-clinical stage used as anti-cancer drug conjugate.

  • Reply to

    However...........

    by theguywho2 Jul 11, 2016 7:38 PM
    theguywho2 theguywho2 Jul 12, 2016 10:37 AM Flag

    Hang on for the ride !

  • Reply to

    However...........

    by theguywho2 Jul 11, 2016 7:38 PM
    theguywho2 theguywho2 Jul 12, 2016 12:29 AM Flag

    Yes, should be enough cash to work this through.

  • Reply to

    However...........

    by theguywho2 Jul 11, 2016 7:38 PM
    theguywho2 theguywho2 Jul 11, 2016 7:42 PM Flag

    So, there's that.

  • theguywho2 by theguywho2 Jul 11, 2016 7:38 PM Flag

    However, the most immediate indications of therapeutic activity, objective response rate (ORR) and disease control rate (ORR + stable disease = 4 months), showed a near doubling in the aldoxorubicin arm compared to investigator's choice, including in patients who previously received treatment with doxorubicin. Disease control rate for aldoxorubicin was significantly greater than investigator's choice therapy in the intent-to-treat population (p=0.048) as well as in patients who received prior doxorubicin (p=0.0415). Patients continue to be followed for overall survival (OS), a secondary endpoint of the trial.

    The company is also developing; in Phase IIb clinical trial in small cell lung cancer; in Phase II clinical trial in HIV-related Kaposi's sarcoma; in Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); in Phase Ib trial in combination with ifosfamide in patients with STS; and in Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. Also a Phase Ib pharmacokinetics clinical trial in patients with metastatic solid tumors. The company is also developing DK049 that is in pre-clinical stage used as anti-cancer drug conjugate.

  • theguywho2 by theguywho2 Jul 8, 2016 2:02 PM Flag

    The new dividend yield on ACGYX is 2,36%, monthly. This is now a pure safe haven money play now.
    It appears they will not be leveraging to the degree that the open end ACG did. Being that the 10 year
    treasury notes are at 1.36%, this is not so bad.

CRZO
34.23-0.55(-1.58%)1:26 PMEDT